Website Notice: We are still working out the bugs on our website. Please let us know if you spot any issues or experience any problems!
Evidence-Based Literature & Citations

Neurofibromatosis Medical Research

Direct access to published peer-reviewed journal papers, clinical trials, landmark diagnostic guidelines, and official FDA approvals with complete citations and links.

Consensus Literature

Landmark Clinical & Diagnostic Guidelines

Major peer-reviewed publications establishing internationally recognized diagnostic criteria and clinical surveillance protocols.

📜

Revised 2021 Diagnostic Criteria for NF1 and Schwannomatosis

Genetics in Medicine (Official Journal of the ACMG / Nature)

DOI: 10.1038/s41436-021-01170-5

Authors: Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, et al.

Citation: Genet Med. 2021;23(8):1506-1513.

The definitive international consensus publication establishing updated diagnostic criteria incorporating next-generation molecular genetic sequencing, updated cutaneous definitions, and standardized schwannomatosis classification.

🩺

Clinical Care and Health Supervision for Children with Neurofibromatosis Type 1

Pediatrics (Official Journal of the American Academy of Pediatrics)

DOI: 10.1542/peds.2019-0660

Authors: Miller DT, Freedenberg D, Schorry E, Ullrich NJ, Viskochil D, Korf BR.

Citation: Pediatrics. 2019;143(5):e20190660.

Comprehensive pediatric surveillance guidelines detailing annual clinical evaluations, blood pressure monitoring, ophthalmologic screening for optic pathway gliomas, and orthopedic assessments.

📑

Consensus Recommendations for Diagnostic and Clinical Management in Schwannomatosis

Genetics in Medicine

DOI: 10.1016/j.gim.2022.02.007

Authors: Evans DG, Salvador H, Chang VY, Erez A, Plotkin SR, et al.

Citation: Genet Med. 2022;24(6):1178-1191.

Standardized guidelines providing clinical diagnostic criteria, multigene panel recommendations for SMARCB1 and LZTR1 variants, pain management protocols, and imaging surveillance.

Targeted Therapies

FDA-Approved MEK Inhibitors for NF1 Plexiform Neurofibromas

The development of targeted MEK inhibitors represents a historic shift from surgical-only approaches to molecular precision medicine for inoperable plexiform tumors.

💊

Selumetinib (Koselugo)

Oral MEK Inhibitor

Pediatric Approval (Age 1+) & Adult Expansion (Nov 2025)

Key Published Trial Citation

Gross AM, Wolters PL, Dombi E, et al. Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med. 2020;382(15):1430-1442.

Trial Overview

Koselugo was originally approved by the FDA for pediatric patients (age 1 and older) with NF1 and symptomatic, inoperable plexiform neurofibromas following the landmark SPRINT Phase II trial. In November 2025, the FDA expanded approval to include adult patients with NF1 and symptomatic, inoperable plexiform neurofibromas.

Clinical Impact

Established the first FDA-approved systemic therapy for NF1 plexiform neurofibromas, demonstrating sustained tumor volume reduction, pain reduction, and improved mobility.

🧪

Mirdametinib (Gomekli)

Oral MEK1/2 Inhibitor

FDA Approved in February 2025

Key Published Trial Citation

Weiss BD, Wolters PL, Plotkin SR, et al. NF106 / ReNeu: A Pivotal Phase 2b Study of Mirdametinib in Children and Adults with NF1-Associated Inoperable Plexiform Neurofibromas. J Clin Oncol. 2024;42(16_suppl):3001.

Trial Overview

The FDA approved Gomekli in February 2025 for adults and pediatric patients age 2 and older with NF1 and symptomatic plexiform neurofibromas not amenable to complete resection. The approval was supported by robust multi-cohort efficacy and safety data from the ReNeu trial.

Clinical Impact

Provides an additional targeted oral MEK inhibitor option for both adults and children, showing meaningful decreases in tumor burden and patient-reported pain scores.

🧠Psychosocial & Mental Health Literature

Published Medical Journals on Mental Health in NF

Peer-reviewed studies documenting anxiety, depression, cognitive load, and evidence-based psychological interventions in neurofibromatosis.

🌪️

Anxiety, Depression & Illness Uncertainty

Orphanet Journal of Rare Diseases

Direct Medical Journal Citation

Depression, anxiety, and illness perceptions in adults with neurofibromatosis types 1 and 2
Cohen JS, Levy HP, Sloane K, et al. Orphanet J Rare Dis. 2015;10:148.

PMID: 26611394

Key Research Findings

Peer-reviewed research demonstrates that individuals living with NF1 and NF2 experience significantly higher rates of clinical anxiety and depressive symptoms compared to population baselines. Psychological distress is driven by the unpredictable timing of tumor complications, cutaneous visibility, chronic pain, and potential sensory impairment.

Clinical Takeaway

Routine psychological screening, empathetic communication, and proactive mental health support must be standard components of comprehensive <span class="font-bold bg-gradient-to-r from-teal-500 to-red-500 bg-clip-text !text-transparent inline-block">NF</span> clinical care.

🧩

Cognitive Load, ADHD & Executive Functioning

Journal of Child Neurology

Direct Medical Journal Citation

Executive function deficits and ADHD symptoms in children with neurofibromatosis type 1
Pride NA, Payne JM, North KN. J Child Neurol. 2012;27(7):853-860.

PMID: 22467554

Key Research Findings

Neuropsychological literature describes ADHD and executive dysfunction among children and adolescents with NF1. Working memory challenges, visual-spatial processing hurdles, and cognitive fatigue can heighten academic vulnerability and everyday stress.

Clinical Takeaway

Early neuropsychological evaluations directly inform 504 and IEP school accommodations, executive coaching, and targeted behavioral therapies.

🧠

Acceptance & Commitment Therapy (ACT) for Chronic Pain

Pediatric Blood & Cancer

Direct Medical Journal Citation

Acceptance and Commitment Therapy for adolescents and young adults with neurofibromatosis type 1 and chronic pain
Martin S, Wolters PL, Toledo-Tamula MA, et al. Pediatr Blood Cancer. 2020;67(3):e28094.

PMID: 31821731

Key Research Findings

This clinical trial evaluated Acceptance and Commitment Therapy (ACT) for youth and young adults with NF1 and plexiform-related chronic pain, demonstrating statistically significant decreases in pain interference and psychological distress alongside improvements in daily functioning.

Clinical Takeaway

Evidence-based psychological interventions provide actionable cognitive tools that reduce the debilitating daily impact of neuropathic pain.

🌱

Mind-Body Resilience & Quality of Life

Neurology & Genet Med

Direct Medical Journal Citation

Virtual mind-body resilience intervention for adults with neurofibromatosis: A randomized clinical trial
Plotkin SR, Merker VL, Muzikansky A, et al. Neurology. 2021;96(10):e1470-e1481.

PMID: 33177227

Key Research Findings

A randomized controlled trial testing a virtual mind-body resilience program (the Relaxation Response Resiliency Program) for adults with NF1, NF2, and schwannomatosis reported sustained improvements in quality of life, pain coping, and emotional resilience.

Clinical Takeaway

Accessible telehealth and group psychosocial interventions provide scalable, transformative emotional benefits for rare disease communities.

Translational Science

Active Research Pipelines & Preclinical Frontiers

Ongoing preclinical models and exploratory investigations investigating upstream gene editing, topical agents, and neuro-inflammation pathways.

🧬

Gene Editing & Preclinical Antisense Oligonucleotide Therapies

Molecular Therapy & Human Molecular Genetics

Anastasaki C, Woo AS, Messiaen LM, Gutmann DH. Mol Ther. 2020;28(9):2060-2072.

Preclinical investigations utilizing CRISPR/Cas9, base editing, and exon skipping approaches aim to correct specific pathogenic NF1 and NF2 nonsense mutations, investigating restoration of functional neurofibromin and merlin protein synthesis at the cellular level.

Clinical Status: These gene-directed approaches remain experimental in laboratory models and are not currently approved treatments.
🔬

Cutaneous Neurofibroma Interventions & Topical Formulations

British Journal of Dermatology & Lancet Oncology

Cannon A, Chen MJ, Li K, et al. Br J Dermatol. 2021;184(6):1021-1030.

Clinical investigations evaluating topical MEK inhibitor formulations, fractional CO2 laser ablation, and high-frequency electrosurgical removal continue to study safety, cosmetic outcomes, and symptom relief for individuals with extensive cutaneous neurofibroma burdens.

Clinical Status: Topical agents and experimental procedural protocols are evaluated in ongoing clinical trials.
⚡

Neuropathic Pain Mechanisms & Neuro-Inflammation

Pain & Neuro-Oncology

Ostrow KL, Donaldson K, Bergner A, et al. Pain. 2015;156(11):2219-2226.

Research into the neuro-inflammatory microenvironment surrounding schwannomas identifies novel neuropathic pain pathways driven by SMARCB1 and LZTR1 variants, guiding targeted non-opioid pharmaceutical research.

Clinical Status: Mechanistic pain discoveries inform ongoing investigational drug studies and clinical trial design.
Trusted Portals & Direct Links

Credible Medical Journals & Research Portals

When researching neurofibromatosis, accessing peer-reviewed medical publications and accredited data portals directly ensures scientific accuracy and safety.

📚

New England Journal of Medicine (NEJM)

Pivotal clinical trial publications on systemic NF pharmacotherapies and randomized controlled studies.

📰

The Lancet Oncology & Neurology

Comprehensive neurological reviews, international diagnostic consensus criteria, and clinical trial outcomes.

🧠

Neuro-Oncology (Oxford Academic)

Official journal of the Society for Neuro-Oncology, publishing clinical and translational research on nerve sheath tumors.

🧬

Genetics in Medicine (ACMG / Nature)

Official journal of the American College of Medical Genetics and Genomics (ACMG), covering genetic diagnostics and clinical guidelines.

🏛️

ClinicalTrials.gov (NIH / NLM Registry)

Comprehensive federal database of active, recruiting, and completed clinical trials evaluating therapies for NF1, NF2-related schwannomatosis, and other forms.

💻

CTF NF Data Portal (Sage Bionetworks)

Open-access genomic, proteomic, and pharmacological data repository accelerating collaborative rare disease discoveries.

Advocacy & Literacy

How to Evaluate Clinical Studies

Navigating medical journal articles can feel overwhelming. Understanding the clinical trial hierarchy empowers you to discuss new findings confidently with your healthcare team.

Key elements to examine include the trial phase (Phase I for safety, Phase II for efficacy, Phase III for large comparative trials), sample size, primary endpoints (such as volumetric MRI changes), and inclusion criteria.

🔍

1. Check the Source & Peer-Review Status

Ensure studies appear in indexed, peer-reviewed medical journals or official institutional clinical trial registries.

🧪

2. Differentiate Preclinical vs. Human Data

Cellular and animal model discoveries provide vital early biological insights, while human clinical trials evaluate human safety, tolerability, and tumor response.

🩺

3. Discuss Findings With Your Specialist

Bring study summaries and direct citations to your appointments to evaluate whether FDA-approved therapies, investigational trials, or tailored surveillance fit your clinical profile.

Questions About Research or Clinical Trials?

Ken of the Rocky Mountains LLC connects individuals and families with educational research summaries and custom awareness apparel.